Navigation Links
WHI Findings Published in JAMA Do Not Affect Clinical Guidance for the Appropriate Use of Hormone Therapy
Date:3/4/2008

Hormone Therapy Remains an Important Option for Women Seeking Relief of

Menopausal Symptoms

COLLEGEVILLE, Pa., March 4 /PRNewswire-FirstCall/ -- Observational follow-up data from the Women's Health Initiative (WHI) study published today in the Journal of the American Medical Association (JAMA) provide little new insight into the appropriate use of hormone therapy when it is prescribed to symptomatic, newly menopausal women. Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), believes that hormone therapy, when used appropriately, remains a good health care choice to relieve moderate to severe menopausal symptoms for millions of women seeking treatment.

"Health care professionals and women should be cautious about drawing generalized conclusions with regard to the benefits and risks of hormone therapy based upon an observational follow-up of the WHI. The WHI was conducted in older women and was designed to assess the risks and benefits of hormone therapy for the prevention of heart disease," says Gary L. Stiles, M.D., Executive Vice President and Chief Medical Officer, Wyeth Pharmaceuticals.

The women who participated in the WHI study were predominantly non-symptomatic and were on average 63 years of age, which is more than a decade past the average onset of menopause. In recent years, reanalysis of WHI findings has repeatedly shown that the risks associated with hormone therapy use in this older study population were not consistently shared across all outcomes by the younger subset of women who are more representative of a newly menopausal, hormone therapy user.

"Selectively releasing information contained in the WHI database, without providing the full context of the data assessed, is not in the best interest of menopausal women and their health care professionals and may needlessly cause confusion," says Stiles.

Clinical guidance as outlined in product labeling and patient information for hormone therapy recommends use at the lowest effective dose for the shortest duration of time.

Wyeth continues to support the appropriate use of hormone therapy and encourages women experiencing menopausal symptoms to speak with a health care professional to determine whether it might be the right treatment option for them.

Hormone therapy is not right for all women, and it does not prevent heart disease or dementia. Hormone therapy may increase a woman's chance of heart attack, stroke, breast cancer or blood clots and should be taken at the lowest effective dose for the shortest time based on her goals and risks. If a woman has a uterus, estrogens increase the risk of uterine cancer. Adding a progestin greatly reduces this risk. Women should re-evaluate the use of estrogens and progestins with their health care professional. If a woman is not having symptoms, non-estrogen treatments should be considered before starting therapy to prevent bone loss.

About Wyeth

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products, including with respect to our pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; data generated on our products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS." The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
2. Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress
3. Clinical Study Findings Show Safety and Procedure Success for TopSpin IntraVascular MRI Catheter for the Coronary Arteries
4. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
5. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
6. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
7. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
8. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
9. Vasogens Research Published in European Journal of Neuroscience
10. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
11. Newly Published EPA RCRA Method 6800 Supports AIT Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... June 23, 2016 ReportsnReports.com ... report to its pharmaceuticals section with historic and ... and much more. Complete report on ... pages, profiling 15 companies and supported with 261 ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global Cell ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):